DocDollars

Taro Pharmaceuticals USA, Inc.

NY · United States · Reporting entity ID 100000005687

Total reported 2019–2025
$22.1M
#298 of 2,960 reporting companies — 0% of all reported industry payments
$68K in general payments across 727 records, plus $22.1M in research funding across 2,479 records.

How it breaks down

General payments $68,053
Research funding $22,063,890

Where this comes from

Figures are from the CMS Open Payments “payments grouped by reporting entity” dataset, queried live. Reporting entities are applicable manufacturers and group purchasing organisations required to report under the Sunshine Act.

Summary

Taro Pharmaceuticals USA, Inc. reported $22.1M to US doctors and teaching hospitals from 2019 to 2025, ranking #298 of 2,960 reporting companies. 100% of that was research funding and 0% general payments such as consulting, speaking, food and travel. 727 general payment records and 2,479 research records were filed.

Common questions about Taro Pharmaceuticals USA, Inc.

How much has Taro Pharmaceuticals USA, Inc. paid US doctors?

Taro Pharmaceuticals USA, Inc. reported $22,131,943 to US physicians and teaching hospitals across the 2019–2025 Open Payments program years: $68,053 in general payments, $22,063,890 in research funding.

How does Taro Pharmaceuticals USA, Inc. rank among drug and device companies?

It ranks #298 of 2,960 reporting entities by total reported value, about 0% of all industry payments in the dataset.

Does a payment from Taro Pharmaceuticals USA, Inc. mean a doctor did something wrong?

No. Open Payments records transfers of value such as speaking fees, consulting, meals, travel and research funding. The data shows the relationship, not its effect on prescribing or care.